FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Sheryl Zelenitsky

Research Profile

Chemicals & Drugs

Procedures

Living Beings

Physiology

Microbial Drug Resistance

Concepts & Ideas

Disorders

Pseudomonas Infections

Co-author Network

Publications

TOP 3
Sheryl A Zelenitsky; George G Zhanel; Robert E Ariano; Ethan Rubinstein
Integrating pharmacokinetics, pharmacodynamics and MIC distributions to assess changing antimicrobial activity against clinical isolates of Pseudomonas aeruginosa causing infections in Canadian hospitals (CANWARD).
Sheryl A Zelenitsky; Robert Ariano; Peter Dodek; Harris Iacovides; Anand Kumar; Yazdan Mirzanejad; Ethan Rubinstein
Vancomycin pharmacodynamics and survival in patients with methicillin-resistant Staphylococcus aureus-associated septic shock.
George G Zhanel; Heather Adam; Andrew Denisuik; Alfred Gin; Daryl J Hoban; Philippe R S Lagacé-Wiens; Christopher D Lawson; Joseph P Lynch; Ethan Rubinstein; Frank Schweizer; Sheryl A Zelenitsky; James A Karlowsky
Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Sheryl Zelenitsky (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Sheryl A Zelenitsky; George G Zhanel; Robert E Ariano; Ethan Rubinstein
Integrating pharmacokinetics, pharmacodynamics and MIC distributions to assess changing antimicrobial activity against clinical isolates of Pseudomonas aeruginosa causing infections in Canadian hospitals (CANWARD).
The Journal of antimicrobial chemotherapy 2013;68 Suppl 1():i67-72.
2013: Sheryl A Zelenitsky; Robert Ariano; Peter Dodek; Harris Iacovides; Anand Kumar; Yazdan Mirzanejad; Ethan Rubinstein
Vancomycin pharmacodynamics and survival in patients with methicillin-resistant Staphylococcus aureus-associated septic shock.
International journal of antimicrobial agents 2013;41(3):255-60.
2013: George G Zhanel; Heather Adam; Andrew Denisuik; Alfred Gin; Daryl J Hoban; Philippe R S Lagacé-Wiens; Christopher D Lawson; Joseph P Lynch; Ethan Rubinstein; Frank Schweizer; Sheryl A Zelenitsky; James A Karlowsky
Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination.
Drugs 2013;73(2):159-77.
2012: Sheryl A Zelenitsky; Robert E Ariano; Margo L McCrae; Lavern M Vercaigne
Initial vancomycin dosing protocol to achieve therapeutic serum concentrations in patients undergoing hemodialysis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2012;55(4):527-33.
2012: George G Zhanel; Heather Adam; Brandon Findlay; Alfred Gin; Daryl J Hoban; Christopher D Lawson; Joseph P Lynch; Ethan Rubinstein; Frank Schweizer; Andrew Walkty; Sheryl A Zelenitsky; James A Karlowsky
Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin.
Expert review of anti-infective therapy 2012;10(4):459-73.
2011: Peter J Zed; Mary H H Ensom; Janice Irvine-Meek; Salmaan Kanji; Sheri L Koshman; Marc Perreault; Richard S Slavik; Kerry Wilbur; Sheryl A Zelenitsky
Evaluation of the research grant program of the Foundation of the Canadian Society of Hospital Pharmacists, 1995-2008.
The Canadian journal of hospital pharmacy 2011;64(6):399-404.
2011: Sheryl A Zelenitsky; Noha Alkurdi; Robert E Ariano; Zhanni Weber; George Zhanel
Preferential emergence of reduced vancomycin susceptibility in health care-associated methicillin-resistant Staphylococcus aureus isolates during continuous-infusion vancomycin therapy in an in vitro dynamic model.
Antimicrobial agents and chemotherapy 2011;55(7):3627-30.
2011: George G Zhanel; Emma Rossnagel; Kim Nichol; Lauren Cox; James A Karlowsky; Sheryl A Zelenitsky; Ayman Noreddin; Daryl J Hoban
Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus, heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus and vancomycin-resistant S. aureus using an in vitro model.
The Journal of antimicrobial chemotherapy 2011;66(6):1301-5.
2011: Jared L Crandon; Robert E Ariano; Sheryl A Zelenitsky; Anthony M Nicasio; Joseph L Kuti; David P Nicolau
Optimization of meropenem dosage in the critically ill population based on renal function.
Intensive care medicine 2011;37(4):632-8.
2011: Sheryl A Zelenitsky; Robert E Ariano; George G Zhanel
Pharmacodynamics of empirical antibiotic monotherapies for an intensive care unit (ICU) population based on Canadian surveillance data.
The Journal of antimicrobial chemotherapy 2011;66(2):343-9.
2011: Rebecca A Keel; Sheryl A Zelenitsky; George G Zhanel; David P Nicolau
Pharmacodynamic profiling of antimicrobials against Gram-negative respiratory isolates from Canadian hospitals.
The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie médicale / AMMI Canada 2011;22(4):132-6.
2010: Sheryl A Zelenitsky; Robert E Ariano
Support for higher ciprofloxacin AUC 24/MIC targets in treating Enterobacteriaceae bloodstream infection.
The Journal of antimicrobial chemotherapy 2010;65(8):1725-32.
2010: George G Zhanel; Divna Calic; Frank Schweizer; Sheryl A Zelenitsky; Heather Adam; Philippe R S Lagacé-Wiens; Ethan Rubinstein; Alfred Gin; Daryl J Hoban; James A Karlowsky
New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.
Drugs 2010;70(7):859-86.
2010: Robert E Ariano; Daniel S Sitar; Sheryl A Zelenitsky; Ryan Zarychanski; Amarnath Pisipati; Stéphane Ahern; Salmaan Kanji; jordi rello; Anand Kumar
Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2010;182(4):357-63.
2009: Anthony M Nicasio; Robert E Ariano; Sheryl A Zelenitsky; Aryun Kim; Jared L Crandon; Joseph L Kuti; David P Nicolau
Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia.
Antimicrobial agents and chemotherapy 2009;53(4):1476-81.
2009: George G Zhanel; Grace Sniezek; Frank Schweizer; Sheryl A Zelenitsky; Philippe R S Lagacé-Wiens; Ethan Rubinstein; Alfred Gin; Daryl J Hoban; James A Karlowsky
Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus.
Drugs 2009;69(7):809-31.
2008: Teresa A Takla; Sheryl A Zelenitsky; Lavern M Vercaigne
Effectiveness of a 30% ethanol/4% trisodium citrate locking solution in preventing biofilm formation by organisms causing haemodialysis catheter-related infections.
The Journal of antimicrobial chemotherapy 2008;62(5):1024-6.
2008: Robert E Ariano; Sheryl A Zelenitsky; Diamond A Kassum
Aminoglycoside-induced vestibular injury: maintaining a sense of balance.
The Annals of pharmacotherapy 2008;42(9):1282-9.
2008: Anil R Maharaj; Sheryl A Zelenitsky; Lavern M Vercaigne
Effect of an ethanol/trisodium citrate hemodialysis catheter locking solution on isolates of Candida albicans.
Hemodialysis international. International Symposium on Home Hemodialysis 2008;12(3):342-7.
2007: T A Takla; Sheryl A Zelenitsky; Lavern M Vercaigne
Effect of ethanol/trisodium citrate lock on microorganisms causing hemodialysis catheter-related infections.
The journal of vascular access 2007;8(4):262-7.
2005: Sheryl A Zelenitsky; Robert E Ariano; Godfrey Harding; Alan Forrest
Evaluating ciprofloxacin dosing for Pseudomonas aeruginosa infection by using clinical outcome-based Monte Carlo simulations.
Antimicrobial agents and chemotherapy 2005;49(10):4009-14.
2005: Robert E Ariano; Adrian Fine; Daniel S Sitar; Stacey Rexrode; Sheryl A Zelenitsky
Adequacy of a vancomycin dosing regimen in patients receiving high-flux hemodialysis.
American journal of kidney diseases : the official journal of the National Kidney Foundation 2005;46(4):681-7.
2005: Robert E Ariano; Sheryl A Zelenitsky; Anna Nyhlén; Daniel S Sitar
An evaluation of an optimal sampling strategy for meropenem in febrile neutropenics.
Journal of clinical pharmacology 2005;45(7):832-5.
2005: Sheryl A Zelenitsky; Harris Iacovides; Robert E Ariano; Godfrey K M Harding
Antibiotic combinations significantly more active than monotherapy in an in vitro infection model of Stenotrophomonas maltophilia.
Diagnostic microbiology and infectious disease 2005;51(1):39-43.
2005: Robert E Ariano; Anna Nyhlén; J Peter Donnelly; Daniel S Sitar; Godfrey K M Harding; Sheryl A Zelenitsky
Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia.
The Annals of pharmacotherapy 2005;39(1):32-8.
2004: Sheryl A Zelenitsky; Robert E Ariano; Godfrey Harding
A reevaluation of empiric therapy for peritoneal dialysis-related peritonitis.
American journal of kidney diseases : the official journal of the National Kidney Foundation 2004;44(3):559-61.
2004: Sheryl A Zelenitsky; Harris Iacovides; Godfrey K M Harding; Robert E Ariano
Effect of antibiotic sequence on combination regimens against Pseudomonas aeruginosa in a multiple-dose, in vitro infection model.
Diagnostic microbiology and infectious disease 2004;49(1):67-70.
2004: Christine Strijack; Godfrey K M Harding; Robert E Ariano; Sheryl A Zelenitsky
Peritoneal fluid titer test for peritoneal dialysis-related peritonitis.
Antimicrobial agents and chemotherapy 2004;48(5):1719-26.
2003: Sheryl A Zelenitsky; Godfrey K M Harding; Siyao Sun; Kiran Ubhi; Robert E Ariano
Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis.
The Journal of antimicrobial chemotherapy 2003;52(4):668-74.
2003: Sheryl A Zelenitsky; Robert E Ariano; Harris Iacovides; Siyao Sun; Godfrey K M Harding
AUC(0-t)/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model.
The Journal of antimicrobial chemotherapy 2003;51(4):905-11.
2002: Sheryl A Zelenitsky; Robert E Ariano; Godfrey K M Harding; Richard E Silverman
Antibiotic pharmacodynamics in surgical prophylaxis: an association between intraoperative antibiotic concentrations and efficacy.
Antimicrobial agents and chemotherapy 2002;46(9):3026-30.
2002: Robert E Ariano; Christine Franczuk; Adrian Fine; Godfrey K M Harding; Sheryl A Zelenitsky
Challenging the current treatment paradigm for methicillin-resistant Staphylococcus epidermidis peritonitis in peritoneal dialysis patients.
Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis 2002;22(3):335-8.
2002: Sheryl A Zelenitsky; Christine Franczuk; Adrian Fine; Robert E Ariano; Godfrey Harding
Antibiotic tolerance of peritoneal bacterial isolates in dialysis fluids.
The Journal of antimicrobial chemotherapy 2002;49(5):863-6.
2002: Lavern M Vercaigne; Sheryl A Zelenitsky; Ian Findlay; Keevin Bernstein; S Brian Penner
An in vitro evaluation of the antibiotic/heparin lock to sterilize central venous haemodialysis catheters.
The Journal of antimicrobial chemotherapy 2002;49(4):693-6.
2000: Sheryl A Zelenitsky; L Barns; I Findlay; Michelle J Alfa; Robert E Ariano; Adrian Fine; Godfrey Harding
Analysis of microbiological trends in peritoneal dialysis-related peritonitis from 1991 to 1998.
American journal of kidney diseases : the official journal of the National Kidney Foundation 2000;36(5):1009-13.
2000: Sheryl A Zelenitsky; R E Silverman; Harry W Duckworth; Godfrey K M Harding
A prospective, randomized, double-blind studyof single high dose versus multiple standard dose gentamicin both in combination withmetronidazole for colorectal surgicalprophylaxis.
The Journal of hospital infection 2000;46(2):135-40.
1999: Sheryl A Zelenitsky; B Booker; Nancy Laing; James A Karlowsky; Daryl J Hoban; George G Zhanel
Synergy of an investigational glycopeptide, LY333328, with once-daily gentamicin against vancomycin-resistant Enterococcus faecium in a multiple-dose, in vitro pharmacodynamic model.
Antimicrobial agents and chemotherapy 1999;43(3):592-7.
1998: George G Zhanel; James A Karlowsky; Sheryl A Zelenitsky; MA Turik; Daryl J Hoban
Susceptibilities of Candida species isolated from the lower gastrointestinal tracts of high-risk patients to the new semisynthetic echinocandin LY303366 and other antifungal agents.
Antimicrobial agents and chemotherapy 1998;42(9):2446-8.
1998: Sheryl A Zelenitsky; James A Karlowsky; Daryl J Hoban; Amin Kabani; George G Zhanel
Once versus thrice daily tobramycin alone and in combination with ceftazidime, ciprofloxacin and imipenem in an in vitro pharmacodynamic model.
Chemotherapy 1998;44(1):1-6.
1997: James A Karlowsky; G A Harding; Sheryl A Zelenitsky; Daryl J Hoban; Amin Kabani; TV Balko; MA Turik; George G Zhanel
In vitro kill curves of a new semisynthetic echinocandin, LY-303366, against fluconazole-sensitive and -resistant Candida species.
Antimicrobial agents and chemotherapy 1997;41(11):2576-8.
1997: James A Karlowsky; Daryl J Hoban; Sheryl A Zelenitsky; George G Zhanel
Altered denA and anr gene expression in aminoglycoside adaptive resistance in Pseudomonas aeruginosa.
The Journal of antimicrobial chemotherapy 1997;40(3):371-6.
1997: James A Karlowsky; George G Zhanel; TV Balko; Sheryl A Zelenitsky; Amin Kabani; Daryl J Hoban
In vitro antifungal activity of BMS-181184 against systemic isolates of Candida, Cryptococcus, and Blastomyces species.
Diagnostic microbiology and infectious disease 1997;28(4):179-82.
1997: Sheryl A Zelenitsky; James A Karlowsky; George G Zhanel; Daryl J Hoban; T Nicas
Time-kill curves for a semisynthetic glycopeptide, LY333328, against vancomycin-susceptible and vancomycin-resistant Enterococcus faecium strains.
Antimicrobial agents and chemotherapy 1997;41(6):1407-8.
1997: James A Karlowsky; Sheryl A Zelenitsky; George G Zhanel
Aminoglycoside adaptive resistance.
Pharmacotherapy 1997;17(3):549-55.
1997: George G Zhanel; James A Karlowsky; G A Harding; TV Balko; Sheryl A Zelenitsky; M Friesen; Amin Kabani; MA Turik; Daryl J Hoban
In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species.
Antimicrobial agents and chemotherapy 1997;41(4):863-5.
1996: Sheryl A Zelenitsky; George G Zhanel
Phenazopyridine in urinary tract infections.
The Annals of pharmacotherapy 1996;30(7-8):866-8.
1993: Sheryl A Zelenitsky; A Richard
Implementation of an aminoglycoside order review process in a central dispensary.
The Canadian journal of hospital pharmacy 1993;46(6):269-74.